JP Morgan upgrades Illumina to Overweight, raises target to $185
JP Morgan analyst Casey Woodring upgraded Illumina from Neutral to Overweight. The firm raised the price target to $185 from the previous $125.
*this image is generated using AI for illustrative purposes only.
JP Morgan analyst Casey Woodring has upgraded Illumina from Neutral to Overweight, citing a revised outlook for the genomics company. The firm also increased its price target for the stock to $185 from the previous $125.
Rating and Target Changes
The upgrade reflects a shift in the firm's perspective on Illumina's potential performance. The new price target of $185 represents a significant increase from the prior target of $125.
| Metric | Previous Value | New Value |
|---|---|---|
| Rating | Neutral | Overweight |
| Price Target | $125 | $185 |
What specific factors drove the significant increase in the price target from $125 to $185?
How might this upgrade influence investor sentiment and trading volume for Illumina in the short term?
What are the potential risks or challenges that could impact Illumina's ability to meet the revised outlook?
20
Access 50+ Readymade Screeners 
Use 200+ Custom Filters 
Get Full Market Insights 
